<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2403245080
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Novanza
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TAFLUPROST
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.015
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ophthalmic use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution in single-dose container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Single Dose Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        56.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01EE05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What kind of medicine is it and how does it<br />work?<br />Novanza&trade; eye drops contain tafluprost, which<br />belongs to a group of medicines called<br />prostaglandin analogues. Novanza&trade; lowers the<br />pressure in the eye. It is used when the pressure in<br />the eye is too high.<br />What is your medicine for?<br />Novanza&trade; is used to treat a type of glaucoma<br />called open angle glaucoma and also a condition<br />known as ocular hypertension in adults. Both of<br />these conditions are linked with an increase in the<br />pressure within your eye and eventually they may<br />affect your eyesight.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Novanza&trade; :<br />&bull; if you are allergic to tafluprost or any of the other<br />ingredients of this medicine (listed in section 6).<br />Warnings and precautions<br />Talk to your doctor, pharmacist or nurse before<br />using Novanza&trade; .<br />Please note that Novanza&trade; may have the<br />following effects and that some of them may be<br />permanent:<br />&bull; Novanza&trade; may increase the length, thickness,<br />colour and/or number of your eyelashes and may<br />cause unusual hair growth on your eyelids.<br />&bull; Novanza&trade; may cause darkening of the colour of<br />the skin around the eyes. Wipe off any excess<br />solution from the skin. This will reduce the risk of<br />skin darkening.<br />&bull; Novanza&trade; may change the colour of your iris<br />(the coloured part of your eye).<br />If Novanza&trade; is used in one eye only, the colour<br />of the treated eye may permanently become<br />different from the colour of the other eye.<br />&bull; Novanza&trade; may cause hair growth in areas<br />where the solution comes repeatedly in contact<br />with the skin surface.<br />Tell your doctor<br />&bull; if you have kidney problems<br />&bull; if you have liver problems<br />&bull; if you have asthma<br />&bull; if you have other eye diseases.<br />Children and adolescents<br />Novanza&trade; is not recommended for children and<br />adolescents below 18 years due to a lack of data<br />on safety and efficacy.<br />Other medicines and Novanza&trade;<br />Tell your doctor or pharmacist if you are taking,<br />have recently taken or might take other medicines.<br />If you use other medicines in the eye, leave at least<br />5 minutes between putting in Novanza&trade; and the<br />other medication.<br />Pregnancy, breast-feeding and fertility<br />If you may become pregnant, you must use<br />an effective method of birth control during<br />Novanza&trade; therapy.<br />Do not use Novanza&trade; if you are pregnant. You<br />should not use Novanza&trade; if you are<br />breast-feeding. Ask your doctor for advice.<br />Driving and using machines<br />Novanza&trade; has no influence on the ability to drive<br />and use machines. You may find that your vision<br />is blurred for a time just after you put Novanza&trade;<br />in your eye. Do not drive or use any tools or<br />machines until your vision is clear.<br />Novanza&trade; contains phosphates<br />This medicine contains phosphates. If you suffer<br />from severe damage to the clear layer at the front<br />of the eye (the cornea), phosphates may cause in<br />very rare cases cloudy patches on the cornea due<br />to calcium build-up during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or<br />pharmacist has told you. Check with your doctor<br />or pharmacist if you are not sure.<br />The recommended dose is 1 drop of<br />Novanza&trade; in the eye or eyes, once daily in the<br />evening. Do not instil more drops or use more<br />often than as instructed by your doctor. This may<br />make Novanza&trade; less effective.<br />Only use Novanza&trade; in both eyes if your doctor<br />told you to.<br />For use as eye drops only. Do not swallow.<br />Instructions for use:<br />When you start a new pouch:<br />Do not use the single-dose containers if the pouch<br />is broken.<br />Every time you use Novanza&trade; :<br />1. Wash your hands.<br />2. Take the strip of containers from the pouch.<br />3. Detach one single-dose container from the strip.<br />4. Put the remaining strip back in the pouch and<br />fold the edge to close the pouch.<br />5. Make sure that the solution is in the bottom part<br />of the single-dose container.&nbsp;6. To open the container, twist off the tab.&nbsp;7. Tilt your head backwards.<br />8. Place the tip of the container close to your eye.</p><p>9. Pull the lower eyelid downwards and look up.<br />10. Gently squeeze the container and let one drop<br />fall into the space between the lower eyelid and<br />the eye.</p><p>11. Close your eye for a moment and press the<br />inner corner of the eye with your finger for about<br />one minute. This helps to prevent the eye drop<br />from draining down the tear duct.<br />12. Wipe off any excess solution from the skin<br />around the eye.</p><p>If a drop misses your eye, try again.<br />If your doctor has told you to use drops in both<br />eyes, repeat steps 7 to 12 for your other eye. The<br />contents of one single-dose container are sufficient<br />for both eyes. Discard the opened container with<br />any remaining contents immediately after use.<br />If you use other medicines in the eye, leave at<br />least 5 minutes between putting in Novanza&trade; and<br />the other medication.&nbsp;If you use more Novanza&trade; than you should, it<br />is unlikely to cause you any serious harm. Put in<br />your next dose at the usual time.<br />If the medicine is accidentally swallowed, please<br />contact a doctor for advice.<br />If you forget to use Novanza&trade;, use a single drop<br />as soon as you remember, and then go back to your<br />regular routine. Do not use a double dose to make<br />up for a forgotten dose.<br />Do not stop using Novanza&trade; without asking<br />your doctor. If you stop using Novanza&trade; , the<br />pressure in the eye will increase again. This may<br />cause a permanent injury to your eye.<br />If you have any further questions on the use of this<br />medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side<br />effects, although not everybody gets them. Most<br />side effects are not serious.<br />Common side effects<br />The following may affect up to 1 in 10 people:<br />Effects on the nervous system:<br />&bull; headache.<br />Effects on the eye:<br />&bull; itching of the eye &bull; irritation in the eye<br />&bull; eye pain &bull; redness of the eye<br />&bull; changes in the length, thickness and number of<br />eyelashes &bull; dry eye<br />&bull; foreign body sensation in the eye<br />&bull; discolouration of eyelashes<br />&bull; redness of the eyelids<br />&bull; small spotlike areas of inflammation on the<br />surface of the eye &bull; sensitivity to light<br />&bull; watery eyes &bull; blurred vision<br />&bull; reduction in the eye&rsquo;s ability to see details<br />&bull; change of colour of the iris (may be permanent).<br />Uncommon side effects<br />The following may affect up to 1 in 100 people:<br />Effects on the eye:<br />&bull; change of colour of the skin around the eyes<br />&bull; puffy eyelids &bull; tired eyes<br />&bull; swelling of the eye&rsquo;s surface membranes<br />&bull; eye discharge &bull; inflammation of the eyelids<br />&bull; signs of inflammation inside the eye<br />&bull; discomfort in the eye<br />&bull; pigmentation of the eye&rsquo;s surface membranes<br />&bull; follicles in the surface membranes of the eye<br />&bull; allergic inflammation<br />&bull; abnormal sensation in the eye.<br />Effects on the skin and tissue under the skin:<br />&bull; unusual hair growth on eyelids.<br />Not known: frequency cannot be estimated from<br />the available data<br />Effects on the eye:<br />&bull; inflammation of the iris/uvea (middle layer of the<br />eye)<br />&bull; eyes appear sunken<br />&bull; macular oedema/cystoid macular oedema<br />(swelling of the retina within the eye leading to<br />worsening vision).<br />Effects on the respiratory system:<br />&bull; worsening of asthma, shortness of breath<br />Reporting of side effects<br />If you get any side effects, talk to your doctor,<br />pharmacist or nurse. This includes any possible<br />side effects not listed in this leaflet. By reporting<br />side effects you can help provide more information<br />on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use this medicine after the expiry date<br />which is stated on the single-dose container and the<br />carton after &lsquo;Exp&rsquo;.<br />Store the unopened foil pouches in a refrigerator<br />(2&deg;C - 8&deg;C). Do not open the pouch until you are<br />about to start using the eye drops as unused<br />containers in an open pouch must be discarded 30<br />days after first opening the pouch.<br />After opening the foil pouch:<br />&bull; Keep the single-dose containers in the original<br />foil pouch.<br />&bull; Do not store above 25 &deg;C.<br />&bull; Discard unused single-dose containers after 30<br />days from date of first opening of the foil pouch<br />&bull; Discard an opened single-dose container with any<br />remaining solution immediately after use.<br />Do not throw away any medicines via wastewater<br />or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These<br />measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Novanza&trade; contains<br />- The active substance is tafluprost.<br />Each 1 ml contains 15 micrograms of tafluprost.<br />One singledose container (0.3 ml) contains 4.5<br />micrograms of tafluprost.<br />- The other ingredients are glycerol, sodium<br />dihydrogen phosphate dihydrate, disodium edetate,<br />polysorbate 80 and water for injection.<br />Hydrochloric acid and or sodium hydroxide<br />(to adjust the pH).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Novanza™ is a sterile, clear colorless solution.
Novanza™ is supplied as a 30 single use units,
preservative-free, air tight LDPE units arranged in
6 Alu-Alu covered pouches each contains 5 single
use units.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufacturer<br />Jamjoom Pharmaceuticals Co.,<br />Jeddah, Makkah region, Saudi Arabia.<br />Tel: +966-12-6081111.<br />Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety<br />Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                18-01-2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>إلى أي نوع من الأدویة ینتمي ھذا العقار وكیفیة عملھ؟<br />قطرة للعین على تافلوبروست، وینتمي إلى &trade; تحتوي نوفانزا<br />مجموعة من الأدویة تُسمى نظائر البروستاجلاندین. یعمل<br />على تقلیل الضغط داخل العینین. حیث یُستخدَّم ھذا &trade; نوفانزا<br />العقار في حالات الارتفاع المُفرط للضغط داخل العین.<br />ماھي دواعي استعمال ھذا العقار؟<br />لعلاج نوع من مرض &quot;الجلوكوما&quot;، یسمى &trade; یُستخدم نوفانزا<br />بمرض الزرق مفتوح الزاویة &quot;الجلوكوما&quot; ولعلاج حالة أخرى<br />تُسمى ارتفاع الضغط داخل العین في المرضى من البالغین.<br />وترتبط كلتا الحالتین بارتفاع الضغط داخل العین، واللتان قد<br />تؤثران، في النھایة على الرؤیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>في الحالات الآتیة: &trade; لا تستخدم نوفانزا<br />&bull; إذا كنت تعاني من حساسیة تجاه المادة الفعّالة &quot;تافلوبروست&quot; أو<br />تجاه أيّ مكوّن من المكونات الأخرى الداخلة في تركیب ھذا<br />.( الدَّواء (المُدرجة في القسم رقم ٦<br />تحذیرات واحتیاطات<br />تحدّث إلى طبیبك، الصیدلي أو الممرض(ة) المتابع (ة) لحالتك<br />:&trade; قبل استخدام نوفانزا<br />قد یُسبب الآثار التالیة التي قد یدوم &trade; یُرجى ملاحظة أن نوفانزا<br />بعض منھا:<br />من طول رموش العین وسمكھا ولونھا و/أو &trade; &bull; قد یزید نوفانزا<br />عددھا، وقد یُسبب نمو غیر معتاد للشعر في مناطق الجفون.<br />اسمرار لون الجلد في المنطقة الموجودة &trade; &bull; قد یُسبب نوفانزا<br />حول العینین. لذلك یُرجى مسح المحلول الزائد من على الجلد،<br />حیث سیقلل ذلك من خطر اسمرار الجلد.<br />لون قزحیة العین (الجزء الملوّن من &trade; &bull; قد یغیر نوفانزا<br />العینین).<br />في عین واحدة، فقد یتغیر لون العین التي &trade; عند استخدام نوفانزا<br />تتم معالجتھا عن لون العین الأخرى بشكل دائم.<br />نمو الشعر في المناطق التي یلمس فیھا &trade; &bull; قد یُسبب نوفانزا<br />المحلول سطح الجلد بصورة متكررة.<br />أخبر طبیبك في الحالات التالیة:<br />&bull; إذا كان تعاني من مشكلات بالكلى.<br />&bull; إذا كنت تعاني من مشكلات بالكبد.<br />&bull; إذا كنت تعاني من الربو.<br />&bull; إذا كنت تعاني من أمراض أخرى في العین.<br />المرضى من الأطفال والمراھقین<br />في المرضى من الأطفال &trade; لا یُوصى باستخدام نوفانزا<br />والمراھقین الذین تقلّ أعمارھم عن ۱۸ عامًا؛ وذلك بسبب قلة<br />البیانات الخاصة بأمان وفعالیة استخدام ھذا العقار.<br />مع أدویة أخرى: &trade; استخدام نوفانزا<br />یُرجى إبلاغ طبیبك أو الصیدلي إذا كنت تتناول أو قد تناولت<br />مؤخرًا أو قد تتناول أیّة أدویة أخرى. إذا كنت تستخدم قطرات<br />&trade; أخرى للعین، ینبغي الفصل الزمني بین استخدام نوفانزا<br />والعقار الآخر على الأقل لمدة خمس دقائق.<br />الحمل والرضاعة الطبیعیة والخصوبة<br />إذا كان لدیكِ القدرة على الحمل، فیجب علیكِ استخدام وسیلة فعّالة<br />.&trade; لمنع الحمل أثناء العلاج باستخدام نوفانزا<br />إذا كنتِ حاملًا. ولا تستخدمي &trade; لا تستخدمي نوفانزا<br />إذا كنتِ تمارسین الرضاعة الطبیعیة، ویُرجى استشارة &trade; نوفانزا<br />طبیبكِ.<br />القیادة واستخدام الآلات<br />أي تأثیر في القدرة على القیادة واستخدام الآلات. &trade; لیس لنوفانزا<br />قد تجد أن الرؤیة لدیك غیر واضحة لبعض الوقت بعد وضع<br />في العین. فتجنّب القیادة أو استخدام أيّ آلات أو أدوات &trade; نوفانزا<br />حتى تتحسن الرؤیة مرة أخرى.<br />على الفوسفات &trade; یحتوي نوفانزا<br />یحتوي ھذا الدواء على فوسفات. إذا كنت تعاني من ضرر شدید<br />للطبقة الشفافة في مقدمة العین (القرنیة) ، قد یتسبب الفوسفات في<br />حالات نادرة جدًا في ظھور بقع غائمة على القرنیة بسبب تراكم<br />الكالسیوم خلال فترة العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>استخدم دائمًا ھذا الدَّواء تمامًا كما أخبرك طبیبك أو الصیدلي.<br />استشر طبیبك أو الصیدلي إذا لم تكن متأكدًا من كیفیة الاستخدام.<br />في العین &trade; الجُرعة المُوصى بھا ھي قطرة واحدة من نوفانزا<br />الواحدة أو العینین مرة واحدة یومیًا في المساء. ولا تستخدم<br />قطرات إضافیة عن الجرعة التي حددھا طبیبك، حیث قد یُقلل ذلك<br />.&trade; من فاعلیة نوفانزا<br />في كلتا العینین إلا إذا أخبرك طبیبك بذلك. &trade; لا تستخدم نوفانزا<br />یُستخدم ھذا العقار كقطرات للعین فقط، لا تقمْ ببلعھ.<br />تعلیمات الاستخدام:<br />عند بدء استخدام عبوة خارجیة جدیدة:<br />لا تستخدم القَطَّارَة أحادیة الجرعة إذا كانت الغلاف المعدني<br />مفتوح.<br />علیك القیام بما یلي: ،&trade; في كل مرة تستخدم فیھا نوفانزا<br />۱. اغسل الیدین.<br />۲. أخرج شریط الوحدات من الغلاف المعدني.<br />۳. أفصل الوحدة أحادیة الجرعة من الشریط.<br />٤. أعد المتبقي من الشریط مرة ثانیة داخل الغلاف المعدني مع<br />طيّ وثني الحافّة لإغلاق الغلاف المعدني.<br />٥. تأكد من وجود المحلول في الجزء السفلي من القَطَّارَة أحادیة<br />الجرعة.</p><p>٦. لفتح العبوة، لف رأس الوحدة.</p><p>۷. قم بإمالة رأسك إلى الخلف.<br />۸. ضع طرف الوحدة بالقرب من العین.</p><p>۹. اسحب الجفن السفلي إلى الأسفل وانظر لأعلى.<br />۱۰ . اضغط بلطف على الوحدة وضع نقطة واحدة في المنطقة بین<br />الجفن السفلي والعین.</p><p>۱۱ . اغلق العین للحظة والضغط على الجانب الداخلي للعین<br />بأصبعك لدقیقة واحدة تقریبًا. حیث یُساعد ھذا في منع تصریف<br />قطرة العین أسفل القناة الدمعیة.<br />۱۲ . أمسح المحلول الزائد من على الجلد حول المنطقة المحیطة<br />للعین.</p><p>إذا سقطت القطرة خارج العین، كرر الخطوات السابقة مرة<br />أخرى.<br />إذا أخبرك طبیبك باستخدام قطرات العین في كلتا العینین، كرّر<br />الخطوات من رقم ۷ حتى رقم ۱۲ بالعین الأخرى. وتُعتبر<br />محتویات القَطَّارَة احادیة الجُرعة كافیة لكلتا العینین. قمْ بالتخلص<br />من القطارة المفتوحة وما تبقى بداخلھا بعد الاستخدام مباشرةً.<br />إذا كنت تستخدم أدویة أخرى للعین، ینبغي الفصل الزمني بین<br />والعقار الآخر لمدة خمس دقائق. &trade; استخدام نوفانزا<br />فمن غیر ،&trade; إذا استخدمت كمیة أكثر مما یجب من نوفانزا<br />المرجّح حدوث أي آثار ضارة. وقم فقط باستخدام الجرعة التَّالیة<br />في وقتھا المُعتاد.<br />في حال القیام ببلع ھذا العقار عن طریق الخطأ، یُرجى استشارة<br />الطبیب.<br />فقم بوضع قطرة واحدة بمجرّد ،&trade; إذا أغفلت استخدام نوفانزا<br />تذكرك لذلك الأمر، ثم استمر في استخدامھ حسب الجرعات<br />المُعتادة. لا تستخدم جرعة مضاعفة لتعویض جرعة أغفلتھا.<br />دون استشارة طبیبك. ففي &trade; لا تتوقف عن استخدام نوفانزا<br />فسوف تعاني مرة أخرى من ،&trade; حال توقفك عن استخدام نوفانزا<br />ارتفاع ضغط العین. وقد یؤدي ذلك إلى حدوث إصابة دائمة<br />بالعین.</p><p>إذا كانت لدیك أیّة أسئلة إضافیة حول استخدام ھذا الدَّواء، فاستشر<br />طبیبك ، الصیدلي أو الممرض(ة) المتابعة(ة) لحالتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثلھ مثل كافة الأدویة، قد یُسبب ھذا الدواء، آثارًا جانبیة على<br />الرغم من عدم حدوثھا لجمیع المرضى. ولا تُعتبر معظم ھذه<br />الآثار الجانبیة خطیرة.<br />آثار جانبیة شائعة<br />قد تؤثر ھذه الآثار الجانبیة على ما یصل إلى مریض واحد من<br />بین كل ۱۰ أشخاص:<br />آثار جانبیة خاصة بالجھاز العصبي:<br />&bull; صداع.<br />آثار جانبیة خاصة بالعین:<br />&bull; حكة بالعین.<br />&bull; تھیّج بالعین.<br />&bull; ألم بالعین.<br />&bull; احمرار العین.<br />&bull; تغیّرات في طول رموش العین وسمكھا وعددھا.<br />&bull; جفاف العین.<br />&bull; إحساس بوجود جسم غریب في العین.<br />&bull; تغیر لون رموش العین.<br />&bull; احمرار جفون العین.<br />&bull; ظھور مناطق ملتھبة صغیرة تشبھ البقع على سطح العین.<br />&bull; شعور بحساسیة تجاه الضوء.<br />&bull; امتلاء العینین بالدموع.<br />&bull; عدم وضوح الرؤیة.<br />&bull; انخفاض قدرة العین على رؤیة التفاصیل.<br />&bull; تغیّر في لون قزحیة العین (قد یكون دائماً).<br />آثار جانبیة غیر شائعة<br />قد تُؤثر الآثار التالیة على ما یصل إلى مریض واحد من بین كل<br />۱۰۰ شخص<br />آثار جانبیة خاصة بالعین:<br />&bull; تغیر لون الجلد في المنطقة الموجودة حول العینین.<br />&bull; انتفاخ الجفون.<br />&bull; إجھاد العین.<br />&bull; تورم الأغشیة السطحیة للعین.<br />&bull; إفرازات العین.<br />&bull; التھاب الجفون.<br />&bull; علامات التھاب داخل العین.<br />&bull; شعور بعدم الارتیاح داخل العین.<br />&bull; تغیر لون الأغشیة السطحیة للعین.<br />&bull; وجود جُرَیبات الأغشیة السطحیة للعین<br />&bull; التھاب تحسّسيّ.<br />&bull; شعور غیر طبیعي بالعین.<br />آثار جانبیة خاصة بالجلد وأنسجة أسفل الجلد:<br />&bull; نمو غیر طبیعي للشعر في منطقة الجفون.<br />آثار جانبیة غیر معروف معدّل تكرارھا: لا یمكن تقدیر معدّل<br />تكرارھا من واقع البیانات المتاحة<br />آثار جانبیة خاصة بالعین:<br />&bull; التھاب قزحیة العین/العِنَبیّة &quot;طبقة العین الوقائیّة&quot;(الطبقة<br />الوسطى للعین)<br />&bull; غور العین إلى الداخل (العیون الغائرة).<br />&bull; وذمة البقعة الصفراء/ وذمة البقعة الصفراء الكیسیة (تورّم<br />شبكیة العین مما یؤدي إلى تفاقم الرؤیة)<br />آثار جانبیة خاصة بالجھاز التنفسي:<br />&bull; تفاقم حالة الرّبو، ضیق التنفس<br />الإبلاغ عن الآثار الجانبیة<br />إذا أصبت بأیّة آثار جانبیة، فتحدَّث إلى طبیبك، الصیدلي أو<br />الممرض(ة) المتابعة(ة) لحالتك. ویشمل ذلك أیّة آثار جانبیة<br />مُحتمَلة غیر مُدرجة في ھذه النَّشرة. حیث یمكنك المساعدة في<br />توفیر معلومات إضافیة حول أمان استخدام ھذا الدَّواء من خلال<br />إبلاغك عن الآثار الجانبیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یُحفظ بعیدًا عن متناول و مرأى الأطفال.<br />لا تستخدم ھذا الدَّواء بعد انتھاء تاریخ الصلاحیة المدوّن على<br />.&quot;EXP&quot; القَطَّارَة أحادیة الجُرعة والعبوة الكرتونیة بعد كلمة<br />تحفظ الأغلفة المعدنیة غیر المفتوحة في الثلاجة (عند درجة<br />۸ درجة مئویة). لا تقمْ بفتح الغلاف المعدني إلا إذا - حرارة ۲<br />كنت على وشك بدء استخدام قطرات العین، حیث یلزم التخلّص<br />من القَطَّارَة غیر المستخدمة والموجودة داخل أي غلاف معدني<br />مفتوح بعد مرور ۳۰ یومًا من تاریخ الفتح الأول للغلاف المعدني.<br />بعد فتح الغلاف المعدني<br />&bull; یُرجى حفظ القَطَّارات أحادیة الجرعة داخل الغلاف المعدني<br />الأصلي.<br />&bull; یحفظ في درجة حرارة لا تزید عن ۲٥ درجة مئویة.<br />&bull; قمْ بالتخلّص من القَطَّارَة أحادیة الجرعة غیر المستعملة بعد<br />مرور ۳۰ یومًا من تاریخ الفتح الأول للغلاف المعدني.<br />&bull; قمْ بالتخلّص من القَطَّارات أحادیة الجرعة المفتوحة مع أيّ<br />محلول متبقي بعد الاستعمال مباشرةً.<br />لا تتخلص من الأدویة عن طریق إلقائھا في میاه الصرف الصحي<br />أو مع المخلّفات المنزلیة. استشر الصیدلي الخاص بك حول كیفیة<br />التَّخلص من الأدویة التي لم تعد بحاجة إلیھا. حیث تُساعد ھذه<br />التدابیر في الحفاظ على البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كل ۱ مل یحتوي على ۱٥ میكروجرام تافلوبروست. تحتوي كل<br />عبوة ذات جرعة أحادیة ( ۰٫۳ مل) على ٤٫٥ میكروجرام من<br />تافلوبروست.<br />- المُكَوِّنات الأخرى ھي جلیسیرول، ھیدروجین فوسفات<br />الصودیوم ثنائي الھیدرات ، إدیتیت ثنائي الصودیوم،<br />بولیسوربات ۸۰ و ماء للحقن. حمض الھیدروكلوریك و/ أو<br />ھیدروكسید الصودیوم (لضبط درجة الحموضة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ارة عن محلول معَقَّم، شفّاف وعدیم اللون. &trade; نوفانزا<br />عبوة بھا ۳۰ جرعة أحادیة الإستخدام، من البولي &trade; نوفانزا<br />ایثیلین منخفض الكثافة، محكمة الغلق، خالیة من المواد الحافظة،<br />الجرعات مرتبة في ٦ أغلفة معدنیة كل منھا یحتوي علي<br />٥ جرعات أحادیة الإستخدام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدویة،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- ھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />- المركز الوطني للتیقظ و السلامة الدوائیة<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفیذیة للتیقظ وإدارة الأزمات. o<br />+۹٦٦-۱۱- ھاتف: ۲۰۳۸۲۲۲ o<br />۲۳٤۰-۲۳٥٦- تحویلة: ۲۳۱۷<br />الخط الساخن للإبلاغ: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الالكترون</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            18-01-2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novanza 15 micrograms/ml eye drops, solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 1 ml contains 15 micrograms of tafluprost.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, solution in single-dose container (eye drops).
A clear, colorless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.<br />As monotherapy in patients:<br /> who would benefit from preservative free eye drops<br /> insufficiently responsive to first line therapy<br /> intolerant or contra-indicated to first line therapy<br />As adjunctive therapy to beta-blockers. Tafluprost is indicated in adults &ge; 18 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The recommended dose is one drop of Tafluprost in the conjunctival sac of the affected eye(s) once<br />daily in the evening.<br />The dose should not exceed once daily as more frequent administration may lessen the intraocular<br />pressure lowering effect.<br />For single use only, one container is sufficient to treat both eyes. Any unused solution should be<br />discarded immediately after use.<br />Use in elderly<br />No dosage alteration in elderly patients is necessary.<br />Paediatric population<br />The safety and efficacy of tafluprost in children below age 18 has not yet been established. No data<br />are available.<br />Use in renal/hepatic impairment&nbsp;</p><p>Tafluprost has not been studied in patients with renal/hepatic impairment and should therefore be<br />used with caution in such patients.<br />Method of administration<br />To reduce the risk of darkening of the eyelid skin the patients should wipe off any excess solution<br />from the skin. As with any other eye drops, nasolacrimal occlusion or gently closing the eyelid after<br />administration is recommended. This may reduce the systemic absorption of medicinal products<br />administered via the ocular route.<br />If more than one topical ophthalmic medicinal product is being used, each one should be administered<br />at least 5 minutes apart.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance Tafluprost or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before treatment is initiated, patients should be informed of the possibility of eyelash growth,<br />darkening of the eyelid skin and increased iris pigmentation. Some of these changes may be<br />permanent, and may lead to differences in appearance between the eyes when only one eye is treated.<br />The change in iris pigmentation occurs slowly and may not be noticeable for several months. The<br />change in eye colour has predominantly been seen in patients with mixed coloured irises, e.g. bluebrown,<br />grey-brown, yellow-brown and green-brown. The risk of lifelong heterochromia between the<br />eyes in unilateral cases is obvious.<br />There is a potential for hair growth to occur in areas where tafluprost solution comes repeatedly in<br />contact with the skin surface.<br />There is no experience with tafluprost in neovascular, angle-closure, narrow-angle or congenital<br />glaucoma. There is only limited experience with tafluprost in aphakic patients and in pigmentary or<br />pseudoexfoliative glaucoma.<br />Caution is recommended when using tafluprost in aphakic patients, pseudophakic patients with torn<br />posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid<br />macular oedema or iritis/uveitis.<br />There is no experience in patients with severe asthma. Such patients should therefore be treated with<br />caution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interactions are anticipated in humans since systemic concentrations of Tafluprost are extremely<br />low following ocular dosing. Therefore, specific interaction studies with other medicinal products<br />have not been performed with Tafluprost.<br />In clinical studies Tafluprost was used concomitantly with timolol without evidence of interaction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential/contraception<br />Tafluprost must not be used in women of childbearing age/potential unless adequate contraceptive<br />measures are in place (see section 5.3).</p><p>Pregnancy<br />There are no adequate data from the use of tafluprost in pregnant women.<br />Tafluprost can have harmful pharmacologic effects on pregnancy and/or the fetus/newborn child.<br />Studies in animals have shown reproductive toxicity (see section 5.3). Therefore, Tafluprost should<br />not be used during pregnancy unless clearly necessary (in case no other treatment options are<br />available).<br />Breastfeeding<br />It is unknown whether tafluprost and/or its metabolites are excreted in human milk. A study in rats<br />has shown excretion of tafluprost and/or its metabolites in breast milk after topical administration<br />(see section 5.3).<br />Therefore tafluprost should not be used during breastfeeding.<br />Fertility<br />In female and male rats, mating performance and fertility was unaffected by intravenous tafluprost<br />doses up to 100 microg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tafluprost has minor influence on the ability to drive and use machines. If transient blurred vision<br />occurs at instillation, the patient should wait until the vision clears before driving or using machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, over 1,400 patients have been treated with preserved tafluprost either as<br />monotherapy or as adjunctive therapy to timolol 0.5%. The most frequently reported treatmentrelated<br />adverse event was ocular hyperaemia. It occurred in approximately 13% of the patients<br />participating in the clinical studies with preserved tafluprost in Europe and the US. It was mild in<br />most cases and led to discontinuation on an average in 0.4% of patients participating in the pivotal<br />studies. In a 3-month, phase III study in the US comparing the non-preserved formulation of<br />tafluprost with the non-preserved timolol formulation, ocular hyperemia occurred in 4.1% (13/320) of<br />patients treated with tafluprost.<br />The following undesirable effects related to treatment were reported during clinical trials with<br />tafluprost in Europe and the US after a maximum follow-up of 24 months:<br />Within each frequency grouping, adverse reactions are presented in order of decreasing frequency.&nbsp;</p><p>Nervous system disorders<br />Common (&ge;1/100 to &lt;1/10): headache&nbsp;</p><p>Eye disorders<br />Common (&ge;1/100 to &lt;1/10): eye pruritus, eye irritation, eye pain, conjunctival/ocular hyperaemia,<br />changes in eyelashes (increased length, thickness and number of lashes), dry eye, foreign body<br />sensation in eyes, eyelash discolouration, erythema of eyelid, superficial punctate keratitis (SPK),<br />photophobia, increased lacrimation, blurred vision, reduced visual acuity and increased iris<br />pigmentation.<br />Uncommon (&ge;1/1,000 to &lt;1/100): blepharal pigmentation, eyelid oedema, asthenopia, conjunctival<br />oedema, eye discharge, blepharitis, anterior chamber cells, ocular discomfort, anterior chamber flare,<br />conjunctival pigmentation, conjunctival follicles, allergic conjunctivitis and abnormal sensation in<br />eye.<br />Not known (cannot be estimated from the available data): iritis/uveitis, lid sulcus deepened, macular<br />oedema/cystoid macular oedema.<br />Cases of corneal calcification have been reported very rarely in association with the use of phosphate<br />containing eye drops in some patients with significantly damaged corneas.<br />Respiratory, thoracic, and mediastinal disorders<br />Not known (cannot be estimated from the available data): exacerbation of asthma, dyspnea<br />Skin and subcutaneous tissue disorders<br />Uncommon (&ge;1/1,000 to &lt;1/100): hypertrichosis of eyelid<br />Reporting of suspected adverse reactions<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />Toll free phone: 19999<br />E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose is unlikely to occur after ocular administration.<br />If overdose occurs, treatment should be symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiglaucoma preparations and miotics, prostaglandin analogues<br />ATC code: S01EE05<br />Mechanism of action<br />Tafluprost is a fluorinated analogue of prostaglandin F2&alpha;. Tafluprost acid, the biologically active<br />metabolite of tafluprost, is a highly potent and selective agonist of the human prostanoid FP receptor.<br />Tafluprost acid has a 12-fold higher affinity for the FP receptor than latanoprost. Pharmacodynamic<br />studies in monkeys indicate that tafluprost reduces intraocular pressure by increasing the uveoscleral<br />outflow of aqueous humour.<br />Pharmacodynamic effects<br />The experiments in normotensive and ocular hypertensive monkeys showed that tafluprost is an<br />effective IOP-lowering compound. In the study investigating IOP-reducing effect of tafluprost<br />metabolites only tafluprost acid reduced IOP significantly.<br />When rabbits were treated for 4 weeks with a tafluprost 0.0015% ophthalmic solution once daily, the<br />optic nerve head blood flow was significantly (15%) increased compared to baseline when measured<br />by the laser speckle flowgraphy on Days 14 and 28.<br />Clinical efficacy<br />Reduction of the intraocular pressure starts between 2 and 4 hours after the first administration and<br />maximum effect is reached at around 12 hours after instillation. The duration of effect is maintained<br />for at least 24 hours. Pivotal studies with a tafluprost formulation containing the preservative<br />benzalkonium chloride have demonstrated that tafluprost is effective as monotherapy and showedan&nbsp;additive effect when administered as adjunctive therapy to timolol: In a 6-month study, tafluprost<br />showed a significant IOP-lowering effect of 6 to 8 mmHg at different time points of the day as<br />compared to 7 to 9 mmHg with latanoprost. In a second 6-month clinical study, tafluprost reduced<br />IOP by 5 to 7 mmHg as compared to 4 to 6 mmHg with timolol. The IOP-lowering effect of<br />tafluprost was maintained in the extension of these studies up to 12 months. In a 6-week study, the<br />IOP-lowering effect of tafluprost was compared with its vehicle when used adjunctively with timolol.<br />Compared to baseline values (measured after a 4-week run in on timolol), the additional IOPlowering<br />effects were 5 to 6 mmHg in the timolol-tafluprost group and 3 to 4 mmHg in the timololvehicle<br />group. The preserved and the non-preserved formulations of tafluprost showed a similar IOPlowering<br />effect of over 5 mmHg in a small cross-over study with a 4-week treatment period.<br />Furthermore, in a 3-month study in the US comparing the non-preserved formulation of tafluprost<br />with the non-preserved formulation of timolol, the IOP-lowering effect of tafluprost was between 6.2<br />and 7.4 mmHg at different timepoints whereas that of timolol varied between 5.3 and 7.5 mmHg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />After once daily administration of one drop of unpreserved tafluprost 0.0015% eye drops to both eyes<br />for 8 days, plasma concentrations of tafluprost acid were low and had similar profiles on days 1 and<br />8. The plasma concentrations peaked at 10 minutes after dosing and declined to below the lower limit<br />of detection (10 pg/ml) before one hour after dosing. Mean Cmax (26.2 and 26.6 pg/ml) and AUC0-<br />last (394.3 and 431.9 pg*min/ml) values were similar on days 1 and 8, indicating that a steady drug<br />concentration was reached during the first week of ocular dosing. No statistically significant<br />differences in the systemic bioavailability between the preserved and unpreserved formulation were<br />detected.<br />In a rabbit study, the absorption of tafluprost into the aqueous humour was comparable after a single<br />ocular instillation of unpreserved or preserved tafluprost 0.0015% ophthalmic solution.</p><p>Distribution<br />In monkeys, there was no specific distribution of radiolabelled tafluprost in the iris-ciliary body or<br />choroid including retinal pigment epithelium, which suggested low affinity for melanin pigment. In a<br />whole body autoradiography study in rats, the highest concentration of radioactivity was observed in<br />the cornea followed by the eyelids, sclera and the iris. Outside the eye radioactivity was distributed to<br />the lacrimal apparatus, palate, oesophagus and gastrointestinal tract, kidney, liver, gall bladder and<br />urinary bladder.<br />The binding of tafluprost acid to human serum albumin in vitro was 99% at 500 ng/ml tafluprost acid.</p><p>Biotransformation<br />The principal metabolic pathway of tafluprost in human, which was tested in vitro, is the hydrolysis<br />to the pharmacologically active metabolite, tafluprost acid, which is further metabolized by<br />glucuronidation or beta-oxidation. Products of beta-oxidation, 1,2-dinor and 1,2,3,4-tetranor<br />tafluprost acids, which are pharmacologically inactive, may be glucuronidated or hydroxylated.<br />Cytochrome P450 (CYP) enzyme system is not involved in the metabolism of tafluprost acid. Based<br />on the study in rabbit corneal tissue and with purified enzymes, the main esterase responsible for the<br />ester hydrolysis to tafluprost acid is carboxyl esterase. Butylcholine esterase but not acetylcholine<br />esterase may also contribute to the hydrolysis.<br />Elimination<br />Following once daily administration of 3H-tafluprost (0.005% ophthalmic solution; 5 microl/eye) for<br />21 days to both eyes in rats, approximately 87% of the total radioactive dose was recovered in the<br />excreta. Percent of the total dose excreted in urine was approximately 27-38% and approximately 44-<br />58% of the dose was excreted in the feces.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, systemic repeated dose toxicity, genotoxicity and carcinogenic potential. As with<br />other PGF2 agonists, repeated dose topical ocular administration of tafluprost to monkeys produced<br />irreversible effects on iris pigmentation and reversible enlargement of the palpebral fissure.<br />Increased contraction of rat and rabbit uteri in vitro was observed at tafluprost acid concentrations<br />that exceeded 4 to 40 times, respectively, the maximum plasma concentrations of tafluprost acid in<br />humans. Uterotonic activity of tafluprost has not been tested in human uterus preparations.<br />Reproduction toxicity studies were performed in the rat and rabbit with intravenous administration. In<br />rats, no adverse effects on fertility or early embryonic development were observed at systemic<br />exposure over 12,000 times the maximum clinical exposure based on Cmax or greater than 2,200<br />times based on AUC.<br />In conventional embryo-foetal development studies, tafluprost caused reductions in foetal body<br />weights and increases in post-implantation losses. Tafluprost increased the incidence of skeletal<br />abnormalities in rats as well as the incidence of skull, brain and spine malformations in rabbits. In the<br />rabbit study, plasma levels of tafluprost and its metabolites were below the level of quantification.<br />In a pre- and postnatal development study in rats, increased mortality of newborns, decreased body<br />weights and delayed pinna unfolding were observed in offspring at tafluprost doses greater than 20<br />times the clinical dose.<br />The experiments in rats with radiolabelled tafluprost showed that around 0.1% of the topically<br />applied dose on eyes was transferred into milk. As the half-life of active metabolite (tafluprost acid)<br />in plasma is very short (not detectable after 30 minutes in humans), most of the radioactivity probably&nbsp;represented metabolites with little, or no pharmacologic activity. Based on metabolism of the drug<br />and natural prostaglandins, the oral bioavailability is expected to be very low.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glycerol<br />Edetate Disodium(EDTA)<br />Sodium dihydrogen phosphate dihydrate<br />Polysorbate 80<br />Hydrochloric acid and/or sodium hydroxide (for pH adjustment)<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C -8&deg;C).<br />For storage conditions after first opening of the foil pouch, see section 6.3.<br />After opening the foil pouch:<br />&bull; Keep the single-dose containers in the original foil pouch<br />&bull; Do not store above 25&deg;C<br />&bull; Discard an opened single-dose container with any remaining solution immediately after use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Low-density polyethylene (LDPE) single-dose containers packed in foil pouch. Each single-dose<br />container has a fill volume of 0.3 ml<br />The following pack size is available: 30 x 0.3 ml single-dose containers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                13/June/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>